Apicore US LLC

Apicore, LLC

Sanjay F Thakor

Ravishanker Kovi

Jayaraman Rao Kannapan

Ashish Naik

Shivnath Sahebrao Patil

KeshavRao Rapole

Ananda Babu Thirunavakarasu

Veerabhadra Rao Bobbili

Rajesh A Patel

Gaurav Yadav

Dhakhada Chetana Bharatbhai

Khichi Kuldip Fatehlal

Muralikrishna Madala

Murali Krishna Madala

Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.

Polymorphs of ponatinib hydrochloride

Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.

Processes for making ponatinib and intermediates thereof

Novel synthetic approaches to make 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof are provided.

Methods of making saxagliptin, pharmaceutically acceptable salts and hydrates thereof and intermediates thereof.

Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof

Growing community of inventors

Gujarat, India

Sanjay F Thakor